Skip to main content
GYRE
NASDAQ Life Sciences

Gyre Q3 Revenue $32.9M, Swings to $2.5M Loss; F351 NMPA Decision Due by 1Q27

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$4.01
Mkt Cap
$425.195M
52W Low
$3.97
52W High
$9.14
52W Position info
1.0% above low
Off High info
56% below high
Rel. Volume info
1.8× avg
Market data snapshot near publication time

GYRE is trading near its 52-week low of $3.97 (1.0% above the low) on elevated volume (1.8× avg).

Summary

Gyre reported flat Q3 revenue of $32.9M but a $2.5M net loss versus $1.9M of income a year ago, with cash down to $98.8M. Full-year 2026 revenue guidance of $100.5M-$111.0M was affirmed, and the F351 NMPA decision is expected by year-end 2026 or 1Q27.


Key Events · Earnings and Guidance · GYRE

  • Q3 Revenue Flat, Profit Turns to Loss

    Revenue of $32.9M versus $32.7M a year ago (+1%), while net loss was $2.5M versus $1.9M of net income, and basic EPS fell to $(0.04) from $0.01.

  • Nine-Month Loss Widens to $35.3M

    Year-to-date net loss of $35.3M versus $4.6M of net income in 2025, driven by $6.9M of transaction costs and a $9.3M increase in external clinical research expense tied to the F351 NDA review.

  • Cash Falls to $98.8M

    Cash, short-term deposits, short-term investments and long-term CDs totaled $98.8M at September 30, 2026, down $17.3M (15%) from $116.1M at December 31, 2025.

  • F351 Decision Due by 1Q27

    The NMPA on-site inspection of manufacturing plants and clinical centers is complete; Gyre expects a decision by year-end 2026 or 1Q27 and a launch in 1H27 if approved.


Analysis · GYRE · Life Sciences

Revenue was essentially flat year over year at $32.9M, but the company swung from $1.9M of net income to a $2.5M net loss as operating expenses rose $3.2M. The nine-month picture is far worse: a $35.3M net loss versus $4.6M of income in 2025, with $6.9M of one-time transaction costs from the Cullgen deal and the terminated Pulmatrix merger plus a $9.3M jump in F351 review-related clinical spend. Cash and investments of $98.8M are down $17.3M since December, so the burn is real but the balance sheet still funds operations for now. With the stock trading near its 52-week low of $3.97, the F351 NMPA decision — expected by year-end 2026 or 1Q27, with launch in 1H27 — is the single event that can re-rate the equity; the on-site inspection is already complete, removing a key gating item.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, GYRE was trading at $4.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $425.2M. The 52-week trading range was $3.97 to $9.14. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

GYRE - Latest Insights

GYRE
Nov 05, 2026, 4:07 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $4.01
Real-time Price: $4.27 info
Change: +$0.260 (+6%) info
Market Cap: $485.501M info
GYRE
Aug 07, 2026, 5:00 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $6.67
Real-time Price: $4.27 info
Change: -$2.40 (-36%) info
Market Cap: $485.501M info
GYRE
Aug 07, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.40
Real-time Price: $4.27 info
Change: -$2.13 (-33%) info
Market Cap: $485.501M info
GYRE
Jul 15, 2026, 5:09 PM EDT
Filing Type: 8-K/A
Importance Score:
7
Price at Filing: $6.56
Real-time Price: $4.27 info
Change: -$2.29 (-35%) info
Market Cap: $485.501M info
GYRE
Jun 22, 2026, 7:16 PM EDT
Filing Type: S-3
Importance Score:
8
Price at Filing: $6.34
Real-time Price: $4.27 info
Change: -$2.07 (-33%) info
Market Cap: $485.501M info